Philip Morris International (PM) Q1 2026 earnings review
IQOS Dominates Globally, But U.S. ZYN Hits a Speed Bump
PMI delivered an exceptional quarter with Adjusted EPS surging 16%, fueled by international IQOS momentum and relentless combustible pricing. Smoke-free products now account for 43% of total revenue. However, the U.S. segment—previously the star growth engine—suffered a brutal reversal. U.S. revenues plunged 31% organically and operating income collapsed 75% due to inventory destocking and tough year-over-year promotional comps. Despite the U.S. drag, robust international growth and a strong FY26 earnings outlook demonstrate that the overarching smoke-free transformation is firmly on track.
🐂 Bull Case
For the first time, IQOS surpassed Marlboro to become the #1 nicotine brand in markets where it is present, proving the smoke-free transition is structurally sound and accelerating.
Despite a 5.1% drop in international cigarette volumes, an 8.5% pricing hike drove overall combustible revenue up. Legacy products continue to print cash to fund the transition.
🐻 Bear Case
ZYN U.S. shipments fell 23.5% to 155 million cans. While management blames inventory timing and tough comps, a 75% drop in U.S. operating income is a significant near-term drag.
Reported diluted EPS fell 9.3% to $1.56, heavily impacted by a $0.22 per share non-cash fair value adjustment on a minority shareholding in India, exposing investors to equity volatility.
⚖️ Verdict: 🔴
Bullish. The 75% operating income collapse in the U.S. is alarming but appears transient, driven by inventory swings rather than consumer rejection. With IQOS booming internationally, margins expanding, and legacy pricing holding up, the fundamentals remain rock solid.
Key Themes
IQOS Becomes the #1 Global Brand
Accelerating. The heat-not-burn portfolio continues to lead the global category, in which PMI holds a 77% volume share. Notably, IQOS surpassed Marlboro to become the top nicotine brand in its active markets. HTU adjusted in-market sales grew 10.9%, driven by multi-tier consumable innovation (TEREA, DELIA, LEVIA).
The U.S. ZYN Reversal
Reversing. The U.S. segment hit a wall this quarter. ZYN shipments dropped 23.5% to 155 million cans, and segment Adjusted Operating Companies Income (OCI) crashed 75.3% to $100 million. Management points to distributor inventory movements and challenging promotional comps, noting that Nielsen-estimated offtake actually grew 10%. However, this starkly contradicts the hyper-growth narrative from FY25 and demands close monitoring.
Relentless Combustible Pricing
Stable. Cigarette volumes fell 5.1%, driven by weakness in Indonesia, Russia, and Germany. Yet, an aggressive 8.5% pricing variance completely offset the volume decline, driving 1.0% organic revenue growth and 3.9% organic gross profit growth in the combustible segment. Pricing power remains PMI's most reliable lever.
Unfavorable Geographic Mix
Decelerating. PMI's overall cigarette category share slipped 0.6pp to 24.8%. This was driven by an unfavorable market mix—specifically lower share in Indonesia, Russia, and Turkey, which was only partially offset by gains in Egypt. While pricing covers the gap now, losing share in high-volume emerging markets is a long-term risk.
Middle East Conflict & Energy Macro
Stable. Management explicitly flagged the Middle East conflict as a headwind impacting Global Travel Retail and specific regional shipments. Furthermore, disruptions in energy supply and rising energy costs have been observed across multiple markets. While consumer behavior hasn't shifted yet, these macro factors introduce input cost uncertainties for FY26.
VEEV Reaches Massive Scale
Accelerating. The e-vapor portfolio is finally showing profitable scale. VEEV shipments exceeded 1 billion equivalent units for the first time in a single quarter, growing 94.8% YoY. It now shares the #1 closed pod position in Europe, validating PMI's methodical, profitable approach to a category historically plagued by low margins.
Other KPIs
Down 75.3% organically from $437 million in 25Q1. This massive drop reflects lower ZYN volumes due to trade inventory adjustments, an unfavorable price comparison vs last year's low promo activity, and heavily increased investments in marketing, administration, and research.
Cash used in operations worsened from -$350 million in 25Q1. This is a standard Q1 seasonal dynamic due to working capital requirements, but it stands in stark contrast to the strong full-year guidance of roughly $13.5 billion.
Guidance
Accelerating. The midpoint ($8.435) implies robust 11.9% growth over FY25's $7.54. Excluding currency, the growth is projected at 7.5% to 9.5%. This signals that management views the Q1 U.S. weakness as a transient issue that will not derail annual targets.
Stable. Continues to reflect strong underlying momentum in the international smoke-free business, offset slightly by expected cigarette volume declines of around 3%.
Stable. Shows that operating leverage remains intact. Full-year amortization of acquired intangibles will hit $0.50 per share, but core profitability continues to expand.
Accelerating sequentially from Q1's $1.96. Includes an estimated favorable currency impact of 2 cents. This implies a rapid snap-back in earnings momentum heading into the summer.
Key Questions
U.S. ZYN Inventory Normalization
With ZYN U.S. shipments down 23.5% due to inventory destocking, what is the exact timeline for trade inventories to normalize, and what is the underlying 'true' run-rate of consumer offtake currently?
Combustible Pricing Elasticity
You pushed an 8.5% pricing increase in combustibles this quarter, while volumes fell 5.1%. At what point does this aggressive pricing strategy begin to trigger steeper, non-linear volume declines, especially in pressured macro environments?
ZYN ULTRA FDA Timeline
You mentioned launching ZYN ULTRA in the 'coming months.' What is your confidence level in the FDA review timeline under the nicotine pouch pilot program, and how critical is this launch to reaccelerating U.S. segment growth?
India Investment Exposure
The $0.22 fair value hit from the India minority shareholding wiped out significant reported earnings growth. What is your strategy regarding this stake, and should investors expect continued severe volatility on the EPS line?